Janux Therapeutics Inc (JANX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $695.65M
Last updated: Nov 17, 2026 at 11:06 AM ET
Janux Therapeutics Inc (JANX) Stock Forecast
Analysts expect Janux Therapeutics (JANX) to earn -$1.59 per share in the fiscal year ending Dec 31, 2026, on revenue of $27.42M. Of 18 analysts, 16 rate the stock Buy or Strong Buy, 1 Hold and 1 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 5 estimates for the fiscal year ending Dec 31, 2026 were revised up and 1 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 18 ratings average 2.11, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 89% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 2 | 11.1% |
| Buy | 14 | 77.8% |
| Hold | 1 | 5.6% |
| Sell | 0 | 0.0% |
| Strong Sell | 1 | 5.6% |
- Consensus
- Buy
- Total analysts
- 18
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a larger loss and revenue estimates fall 66.9%.
- Fiscal year ending Dec 31, 2026
- -$1.59
- EPS consensus, revenue $27.42M
- Fiscal year ending Dec 31, 2027
- -$2.58
- EPS consensus, revenue $9.07M
- Next report
- Feb 24, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$1.59 | -$2.29 to -$1.06 | 15 | $27.42M | $20.00M to $48.86M | 14 |
| Dec 31, 2027 | -$2.58 | -$3.42 to -$2.16 | 14 | $9.07M | N/A | 11 |
Quarterly Estimates
The EPS consensus falls from -$0.54 for the quarter ending Dec 31, 2026 to -$0.58 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.54 | -$0.79 to $0.14 | 20 | $7.53M | N/A | 17 |
| Mar 31, 2027 | -$0.58 | -$0.66 to -$0.52 | 7 | $2.73M | N/A | 7 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 11 upward and 1 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 5 | 1 |
| Fiscal year ending Dec 31, 2027 | 6 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$1.76.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$1.59 | -$1.73 | -$1.73 | -$1.73 | -$1.76 | N/A |
| Fiscal year ending Dec 31, 2027 | -$2.58 | -$2.62 | -$2.62 | -$2.62 | -$2.64 | N/A |
| Quarter ending Mar 31, 2027 | -$0.58 | -$0.63 | -$0.63 | -$0.63 | -$0.64 | N/A |
Frequently Asked Questions About JANX
What is the JANX stock forecast?
Consensus analyst estimates put Janux Therapeutics's EPS at -$1.59 for the fiscal year ending Dec 31, 2026, on revenue of $27.42M. The consensus rating from 18 analysts is Buy.
How do analysts rate JANX stock?
Of 18 analysts covering Janux Therapeutics, 2 rate it Strong Buy, 14 Buy, 1 Hold, 0 Sell and 1 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from JANX next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$1.59, with estimates from -$2.29 to -$1.06 from 15 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$2.58, with estimates from -$3.42 to -$2.16 from 14 analysts.
What revenue do analysts expect from Janux Therapeutics next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $27.42M, with estimates from $20.00M to $48.86M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $9.07M.
How many analysts cover JANX?
18 analysts rate Janux Therapeutics stock, and 15 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
JANX pages: Overview, Earnings, Forecast, Financials, Competitors